The Pharmacogenomics and Genomic Medicine Group is a research group undertakes research projects in pharmacogenomics, pharmacology (natural product drug discovery, drug metabolism) and genomic susceptibility to diseases in African populations.

We particularly seek to:

• Understand genomic variations in drug response African population
• Characterize host immune genetics and its influence infectious disease modulation and disease progression
• Identify unique genomic signatures that precipitates non-syndromic sporadic congenital heart defects
• Characterize genomic architectures in rare disease
• Understand pharmacomicrobiome influence on disease outcome and therapeutics

Our over arching goal as a research lab is to be able to translate our outcomes to influence patient treatment and management.

We use human tissue biopsies (blood, serum, plasma, stool) together with our collaborators to achieve our research objectives.

Funding

The PGMG lab has received funding and support from the European Union through the European & Developing Countries Clinical Trials Partnership (EDCTP2) programme, the International Foundation for Science (IFS), The National Research Foundation of South Africa (NRF), the University of Cape Town, South Africa, National Institute of Allergy and Infectious Diseases (NIAID), NIH, USA and the University of Cape Coast, Ghana

Collaborations

• Dr George Boateng Kyei, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
• Dr Tracy Kellerman, Stellenbosch University, Cape Town, South Africa
• Dr Kevin Dzobo, University of Cape Town, South Africa
• Prof. Collet Dandara, University of Cape Town, South Africa
• Prof. Ambroise Wonkam, University of Cape Town, South Africa and John Hopkins University, USA
• Dr Charlotte Osafo, University of Ghana Medical School, Ghana
• Dr Justin Komguep Nono,  Ministry of Scientific Research and Innovation, Cameroon
• Prof. Bruce Carleton, University of British Columbia, Vancouver, Canada